ACRF Accelerate

ACRF ACCELERATE REFERENCES 

ACRF Lung Cancer Screening Centre of Excellence (LUSCE)

  1. Australian Institute of Health and Welfare. Cancer data in Australia. 2022; Available from: https://www.aihw.gov.au/reports/cancer/cancer-data-in-australia/contents/cancer-summary-data-visualisation.
  2. Aberle, D.R., et al., Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med, 2011. 365(5): p. 395-409.
  3. de Koning, H.J., et al., Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. N Engl J Med, 2020. 382(6): p. 503-513.
  4. Sadate, A., et al., Systematic review and meta-analysis on the impact of lung cancer screening by low-dose computed tomography. Eur J Cancer, 2020. 134: p. 107-114.
  5. Australian Institute of Health and Welfare, Rural & remote health.
  6. Australian Institute of Health and Welfare, Cancer in Aboriginal & Torres Strait Islander people of Australia. 2018.
  7. Cancer Australia, Report on the Lung Cancer Screening Enquiry. 2020.
  8. Goldsbury, D.E., et al., Health services costs for cancer care in Australia: Estimates from the 45 and Up Study. PLoS One, 2018. 13(7): p. e0201552.
  9. Goldsbury, D.E., et al., Health services costs for lung cancer care in Australia: Estimates from the 45 and Up Study. PLoS One, 2020. 15(8): p. e0238018.
  10. Lung Foundation Australia, Making Lung Cancer A Fair Fight: A Blueprint for Reform. 2018.
  11. Mazanec, S.R., et al., Work productivity and health of informal caregivers of persons with advanced cancer. Res Nurs Health, 2011. 34(6): p. 483-95.
  12. Pearce, A., et al., Projecting productivity losses for cancer-related mortality 2011 – 2030. BMC Cancer, 2016. 16(1): p. 804.
  13. The Australian Society of Medical Research, Economic Impact of Medical Research in Australia. 2018.
  14. Deloitte Access Economics, Australia’s health and medical research workforce. 2016.

 ACRF Molecular Theranostics Laboratory

  1. Australian Institue of Health and Welfare. Cancer data in Australia. 2022; Available from: https://www.aihw.gov.au/reports/cancer/cancer-data-in-australia/contents/cancer-summary-data-visualisation.
  2. Sumer, B. and J. Gao, Theranostic nanomedicine for cancer. Nanomedicine (Lond), 2008. 3(2): p. 137-40.
  3. Fendler, W.P., et al., Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. JAMA Oncol, 2019. 5(6): p. 856-863.
  4. Hofman, M.S., et al., [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet, 2021. 397(10276): p. 797-804.
  5. Pinter, M., et al., Cancer and liver cirrhosis: implications on prognosis and management. ESMO Open, 2016. 1(2): p. e000042.
  6. Chen, M., et al., Pericyte-targeting prodrug overcomes tumor resistance to vascular disrupting agents. J Clin Invest, 2017. 127(10): p. 3689-3701.
  7. Douglass, A., et al., Antibody-targeted myofibroblast apoptosis reduces fibrosis during sustained liver injury. J Hepatol, 2008. 49(1): p. 88-98.
  8. Alberti, A., L. Chemello, and L. Benvegnù, Natural history of hepatitis C. J Hepatol, 1999. 31 Suppl 1: p. 17-24.
  9. Forner, A., J.M. Llovet, and J. Bruix, Hepatocellular carcinoma. Lancet, 2012. 379(9822): p. 1245-55.
  10. Polaris Observatory HCV Collaborators, Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol, 2017. 2(3): p. 161-176.
  11. Goldsbury, D.E., et al., Health services costs for cancer care in Australia: Estimates from the 45 and Up Study. PLoS One, 2018. 13(7): p. e0201552.
  12. Mazanec, S.R., et al., Work productivity and health of informal caregivers of persons with advanced cancer. Res Nurs Health, 2011. 34(6): p. 483-95.
  13. Pearce, A., et al., Projecting productivity losses for cancer-related mortality 2011 – 2030. BMC Cancer, 2016. 16(1): p. 804.
  14. The Australian Society of Medical Research, Economic Impact of Medical Research in Australia. 2018.
  15. Deloitte Access Economics, Australia’s health and medical research workforce. 2016.

 ACRF Centre for Precision Medicine

  1. Shin et al.
  2. Hofling A, Fotenos AF,  Niu G, Fallah J, Agrawal S, Wang SJ and L Marzella L. Prostate Cancer Theranostics: Concurrent Approvals by the Food and Drug Administration of the First Diagnostic Imaging Drug Indicated to Select Patients for a Paired Radioligand Therapeutic Drug. Journal of Nuclear Medicine July 2022, jnumed.122.264299; DOI: https://doi.org/10.2967/jnumed.122.264299
  3. https://www.fda.gov/news-events/press-announcements/fda-approves-first-psma-targeted-pet-imaging-drug-men-prostate-cancer
  4. Hofman MS, Emmett L, Sandhu S, et al. [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397(10276):797-804.
  5. Juzeniene A, Stenberg VY, Bruland ØS, Larsen RH. Preclinical and Clinical Status of PSMA-Targeted Alpha Therapy for Metastatic Castration-Resistant Prostate Cancer. Cancers (Basel). 2021 Feb 13;13(4):779. doi: 10.3390/cancers13040779. PMID: 33668474; PMCID: PMC7918517.
  6. Langbein T, Weber WA and Eiber M. Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine Journal of Nuclear Medicine September 2019, 60 (Supplement 2) 13S-19S; DOI: https://doi.org/10.2967/jnumed.118.220566
  7. Simon, T., Jackson, E. & Giamas, G. Breaking through the glioblastoma micro-environment via extracellular vesicles. Oncogene 39, 4477–4490 (2020). https://doi.org/10.1038/s41388-020-1308-2
  8. Australian Institute of Health and Welfare. Cancer data in Australia. 2022; Available from: https://www.aihw.gov.au/reports/cancer/cancer-data-in-australia/contents/cancer-summary-data-visualisation.
  9. McDevitt 2018.
  10. Sicklick JK, Kato S, Okamura R, Schwaederle M, Hahn ME, Williams CB, De P, Krie A, Piccioni DE, Miller VA, Ross JS, Benson A, Webster J, Stephens PJ, Lee JJ, Fanta PT, Lippman SM, Leyland-Jones B, Kurzrock R. Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. Nat Med. 2019 May;25(5):744-750. doi: 10.1038/s41591-019-0407-5. Epub 2019 Apr 22. PMID: 31011206; PMCID: PMC6553618.
  11. The Australian Society of Medical Research, Economic Impact of Medical Research in Australia. 2018.
  12. Haslem, D.S., et al., A Retrospective Analysis of Precision Medicine Outcomes in Patients With Advanced Cancer Reveals Improved Progression-Free Survival Without Increased Health Care Costs. J Oncol Pract, 2017. 13(2): p. e108-e119
  13. Mazanec, S.R., et al., Work productivity and health of informal caregivers of persons with advanced cancer. Res Nurs Health, 2011. 34(6): p. 483-95.
  14. Pearce, A., et al., Projecting productivity losses for cancer-related mortality 2011 – 2030. BMC Cancer, 2016. 16(1): p. 804.
  15. Deloitte Access Economics, Australia’s health and medical research workforce. 2016.